From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

Data at ESMO 2025 bolstered the case that blood tests could help doctors sort which patients need additional therapy, and who ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...

Japanese pharma major Astellas Pharma announced that the US Food and Drug Administration (FDA) accepted for priority review a ...

Fran Curtis is a five-time survivor of cancers survivor including breast, appendix and skin cancer, but she told CURE in a ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...